TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00583895

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10% ImCOOH cream
Description: Twenty patients will receive a hydrophilic cream containing 10% ImCOOH and a placebo cream randomized over both limbs twice daily for 14 days with an additional morning application on Day 15.
Study: NCT01979081

Intervention type: OTHER
Intervention: Tailored advice from a physiotherapist and/or an occupational therapist through the myOSCAR patient portal

Intervention type: OTHER
Intervention: Tailored advice from a physiotherapist and/or an occupational therapist through the myOSCAR patient portal
Study: NCT00101582

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palifermin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin chemotherapy
Description: Commercially available cisplatin was administered as an intravenous infusion at a dose of 100 mg/m\^2 on Days 1, 22, and 43.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cisplatin chemotherapy
Description: Commercially available cisplatin was administered as an intravenous infusion at a dose of 100 mg/m\^2 on Days 1, 22, and 43.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy was delivered in 200 cGy daily fractions, 5 days a week.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiotherapy
Description: Radiotherapy was delivered in 200 cGy daily fractions, 5 days a week.
Study: NCT02314338

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Description: In-patient pulmonary rehabilitation including individualized exercise prescription, group based exercise training, education, individual sessions with a multi professional health care team
Study: NCT01056796

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAR™ 27
Description: Creation of a low colorectal (side or pouch low rectal) compression anastomosis in previously radiated patients
Study: NCT01843608

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Intervention
Description: The exercise program will be designed and conducted by qualified in Physical Activity and Sport Sciences. The exercise program will consist in a combined two days per week of supervised training program and one day per week of briskly walking by themselves, following a document, designed by the specialist trainer, which will be given at the beginning of the program. The intervention will have a duration of 12 consecutive weeks. The intensity will be increasing progressively from 65% to 85% of heart rate. The intensity will be controlled by heart rate monitor trademark POLAR FT7 in aerobic exercise and with the number of repetitions (from 8 to 15) and sets (from 2 to 3) in strength exercises. Prescription intensity will be done using Karvonen equation, recommended method to work with risk population.
Study: NCT00751465

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Task Concentration Training
Description: Task Concentration Training TCT following Bögels et al. (1997).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard CBT
Description: Standard CBT following the Clark-and-Wells (1995) model of social anxiety disorder, relying on the German manual for SAD (stangier et al., 2006). Includes the model, role-plays with and without safetey behavior, video-feedback.
Study: NCT04744909

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SafeTrach for tracheotomy
Description: The navigation system is a forceps-like instrument with an outer and an inner shank. The inner shank serves as a ventilation lumen and stabilizes the orotracheal tube in the midline of trachea. The outer shank acts as a three-dimensional guide for the puncturing needle to the midline of trachea
Study: NCT04216043

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RUSF skimmed milk powder
Description: ready-to-use supplementary foods 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RUSF milk protein concentrate and sucrose
Description: ready-to-use supplementary foods 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RUSF soy protein and whey permeate
Description: ready-to-use supplementary foods 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RUSF soy and sucrose
Description: ready-to-use supplementary foods 75 kcal/kg/day (314 kJ/kg/day) and full daily doses of vitamins and micronutrients
Study: NCT03598439

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard IIV4
Description: Standard inactivated influenza vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant
Description: Influenza vaccine that uses a hemagglutinin protein manufactured in insect cells with a baculovirus vector

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell-culture
Description: inactivated influenza vaccine manufactured using mammalian cell lines; current vaccine uses a cell-propagated H3N2 strain.
Study: NCT02171533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil ER
Study: NCT02319148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itraconazole
Description: itraconazole dosed at 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diltiazem
Description: diltiazem dosed at 240 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SR verapamil
Description: SR verapamil dosed at 240 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00489791
Description: PF-00489791 20 mg single dose administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00489791
Description: PF-00489791 20 mg single dose administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00489791
Description: PF-00489791 20 mg single dose administration
Study: NCT04138732

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Improve health behaviors of medical personel
Description: This arm will receive the intervention treatment aimed to help improve their health behaviors, as determined by employee-based steering committee. Interventions will target nutrition, physical activity and stress reduction

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Improve health behaviors of medical personel
Description: This arm will receive the intervention treatment aimed to help improve their health behaviors, as determined by employee-based steering committee. Interventions will target nutrition, physical activity and stress reduction
Study: NCT02702960

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: living related donor partial liver transplantation
Description: HLA matched or haploidentical related living donor partial liver transplant followed by tacrolimus, prednisone, and MMF immunosuppression for \>3 wks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation
Description: 200 cGy total body irradiation (TBI) on Day -1.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow transplant from same donor
Description: BMT using cells from the same Human Leukocyte Antigen (HLA)-matched or -haploidentical living related donor will be performed on Day 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Pre-transplantation low dose cyclophosphamide given day -6 and -5 Post-transplantation high dose cyclophosphamide (PTCy; 50 mg/kg/day) will be administered on Days 3 and 4 with hydration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: administered on Days 3 and 4 with PTCy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: administered daily starting on Day 5 until absolute neutrophil count (ANC) recovery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given after liver transplant for through day -7, stopped on day -6 and restarted on day 5 post BMT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given after liver transplant for through day -7, stopped on day -6 and restarted on day 5 post BMT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given after liver transplant for through day -7, stopped on day -6 and restarted on day 5 post BMT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin
Description: Given from Day -16 to Day -14 prior to bone marrow transplantation on day 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: fludarabine given from Days -6 to Day -2 before BMT
Study: NCT00881270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LACTIC ACID(ND)
Description: Dermacyd Infantile (LACTIC ACID)
Study: NCT02392364

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal Aflibercept Injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal Aflibercept Injection
Study: NCT02287545

Intervention type: PROCEDURE
Intervention: trabeculectomy
Description: Standard trabeculectomy with the use of antimetabolites (mitomycin C) for glaucoma patients with insufficient intraocular pressure (IOP) control taking maximally tolerated IOP-reducing medication, visual field progression despite maximally tolerated IOP-reducing medication, adverse events because of maximally tolerated IOP-reducing medication or nono.compliance.
Study: NCT00005520

Intervention type: DRUG
Intervention: Hydrochlorothiazide

Intervention type: DRUG
Intervention: Hydrochlorothiazide

Intervention type: DRUG
Intervention: Candesartan

Intervention type: DRUG
Intervention: Candesartan
Study: NCT00003666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-hydroxymethylacylfulvene
Description: 11mg/sq m IV infusion over 5 min q day for 5 days each 28 day cycle
Study: NCT00355628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-2246 (fentanyl citrate)
Description: KW-2246
Study: NCT03325114

Intervention type: DRUG
Group type: OTHER
Intervention: Chlorthalidone
Description: Chlorthalidone 12.5-5 mg by mouth daily for 4 weeks
Study: NCT02295956

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Series of physical and quality of life assessments administered to participants, taking about 20 minutes to complete.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants instructed to perform resistance/strengthening exercises for 30 minutes two times each week. Participants to walk 20-30 minutes at least 3 times a week. Participants issued a set of 3 resistance exercise bands with which the exercises can be performed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition Counseling
Description: Within 7 days after being enrolled on study, participant meets with a dietitian to discuss nutrition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Calls
Description: Participants receive phone calls from study staff every 2 weeks for 6 weeks to check for adherence, and if they are having any side effects from the exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Booklet
Description: Exercise instructional booklet given to all participants describing all exercises.
Study: NCT02256007

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Paper and Pencil Assessments
Description: Videogame Assessments

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paper and Pencil Assessments
Description: Videogame Assessments
Study: NCT04558307

Intervention type: DIAGNOSTIC_TEST
Intervention: Pilot a rapid SARS-CoV-2 testing strategy
Description: Rapid testing strategy at an FQHC using Mayo Clinic Laboratory (MCL) diagnostic processing with a real-time polymerase chain reaction assay for SARS-CoV-2 and a Mayo Clinic drive-through collection protocol.

Intervention type: OTHER
Intervention: Community-driven messages to promote COVID-19 testing
Description: A one-time communication about the availability of COVID-19 testing at the FQHC to patients randomized to the intervention group using any available means of communication (text and/or mailed letter).
Study: NCT01506947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: Paricalcitol was administered by intravenous bolus. The initial dose was calculated according to the following formula:~\[Paricalcitol (µg) = iPTH (pg/mL) / 80\]. Subsequent doses were determined based on iPTH, calcium and phosphorus levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Description: Routine darbepoetin alfa use was allowed when transferrin saturation (TSAT) was ≥ 20% and ferritin ≥ 200 μg/L, and hemoglobin level \< 11.5 g/dL. The initial dose was 0.25 to 0.75 µg/kg/week, and the maintenance dose was 0.13 to 0.35 µg/kg/week. Target hemoglobin level was between 10 to 11.5 g/dL.
Study: NCT03239522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-GSK1278863 solution for IV infusion
Description: It is a clear, colorless solution free from visible particulate matter. Participants will receive 10 mL of 5 µg/mL of \[14C\]-GSK1278863 IV solution (total dose: 50 µg) by IV infusion over 1 hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-GSK1278863 oral solution
Description: It is a clear, colorless solution. Participants will receive 125 mL of 200 µg/mL of \[14C\]-GSK1278863 oral solution (total dose: 25 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daprodustat 6 mg oral tablet
Description: It is a 9.0 millimeter (mm) round, white film coated tablet.
Study: NCT02519322

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study: NCT03375593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone 5Mg/Acetaminophen 500Mg Tab
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen 500Mg Tab
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg tab
Description: tablet
Study: NCT03145714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintainance of anesthesia with Intravenous Propofol infusion
Description: The dosage of Intravenous Propofol will be titrated to maintain BIS Values between 40 -60.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maintainance of anesthesia with Intravenous Dexmedetomidine
Description: The dosage of Intravenous Dexmedetomidine will be titrated to maintain BIS Values between 40 -60.
Study: NCT00720096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Doxorubicin
Description: Liposomal Doxorubicin 40 mg/m2 q 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: 1. Topotecan (daily x 5 days of a 21 day cycle)~2. Per amendment #15: Topotecan (days 1, 8, 15 of a 28 day cycle)
Study: NCT01229852

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DSF-rTMS
Description: Effective Transcranial Magnetic Stimulation
Study: NCT01444703

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: licorice solution
Description: licorice (0.5 g)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sugar solution
Description: sugar (5 g).
Study: NCT02502253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: grape seed polyphenolic extract, resveratrol
Description: Bioactive Dietary Polyphenol Preparation (BDPP) is a combination of two nutraceutical preparations (grape seed polyphenolic extract \[GSE\], and resveratrol) that contain abundant concentrations of polyphenols.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: grape seed polyphenolic extract, resveratrol
Description: Bioactive Dietary Polyphenol Preparation (BDPP) is a combination of two nutraceutical preparations (grape seed polyphenolic extract \[GSE\], and resveratrol) that contain abundant concentrations of polyphenols.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: grape seed polyphenolic extract, resveratrol
Description: Bioactive Dietary Polyphenol Preparation (BDPP) is a combination of two nutraceutical preparations (grape seed polyphenolic extract \[GSE\], and resveratrol) that contain abundant concentrations of polyphenols.
Study: NCT00055978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: Given orally. 400mg twice daily for 6 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given orally
Study: NCT04461665

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vitamin D
Description: vitamin D supplement 10 μg daily for 2 months
Study: NCT02503943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide and Mitiglinide
Description: Liraglutide(1.2mg/d) and Mitiglinide (50mg, 3/d)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin and Mitiglinide
Description: Metformin(500mg, 3/d) and Mitiglinide(50mg, 3/d)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitiglinide
Description: Mitiglinide (50mg, 3/d)
Study: NCT01781286

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High Protein
Description: 250 kcal; 40% Protein; 40% Carbohydrate; 20% Fat

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low Protein
Description: 5% Protein; 50% Carbohydrates; 45% Fat
Study: NCT00939653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: 40 mg/m2/day IV over 2 hours (given at hours 0 to 2) on days 1 through 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100 mg/m2/day IV over 2 hours (given at hours 2 to 4) on days 1 through 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 440 mg/m2/day IV as a 30-60 minute infusion (given at hours 4 to 5) on days 1 through 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Administered in Courses 1 and 2 only. 5 micrograms/kg/day IV or SC will begin on Day 6 and end when the ANC is \> 1000 x 2 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given intrathecally on day 1 at the dose defined by age below:~30 mg for patients age 1-1.99 50 mg for patients age 2-2.99 70 mg for patients \>3 years of age
Study: NCT02511405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VB-111 + bevacizumab
Description: VB-111 will be administered intravenously at a dose of 1x10e13 VPs every 2 months~Bevacizumab will be administered intravenously at a dose of 10mg/kg every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab will be administered intravenously at a dose of 10mg/kg every 2 weeks
Study: NCT06447883

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle modification program
Description: The LMP included 12 treatment modules which was administered by the occupational therapist with a national occupational therapist license and a certification from the USC Lifestyle Redesign® course in 2001. The experimental group engaged in 24 weekly group sessions, each lasting approximately 2 hours. Each session started with stretching, followed by knowledge sharing, group discussion, and activities participation which aligned with the session's themes and discussion topics. The four strategies, including didactic presentation, peer exchange, direct experience, and personal exploration, were employed to deliver the treatment module content. Following these strategies, the primary researcher emphasized the connection between participants' personal meanings, individual contexts, and occupations. Afterward, participants were encouraged to formulate a personalized action plan and integrate what they had learnt into their daily routine.
Study: NCT02922868

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoSheath CST-5000 Scope
Description: Cystoscopic procedures will be performed using the EndoSheath CST-5000 Scope.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Olympus Visera Elite OTV-S190 Scope
Description: Cystoscopic procedures will be performed using the Olympus Visera Elite OTV-S190 Scope
Study: NCT00766688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVE5530
Description: * one tablet in the evening with dinner~* in addition to high doses of statin treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVE5530
Description: * one tablet in the evening with dinner~* in addition to high doses of statin treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * one tablet in the evening with dinner~* in addition to high doses of statin treatment
Study: NCT03756857

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Afterload Transfer
Description: Embryo transfer is done by using afterload transfer method

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trial followed by transfer
Description: Embryo transfer is done by using afterload transfer method
Study: NCT03417544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATEZOLIZUMAB
Description: (IV) every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PERTUZUMAB
Description: Loading dose, followed every 3 weeks thereafter by a predetermined dose in the protocol via IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRASTUZUMAB
Description: Predetermined dose per protocol via IV, weekly for 24 weeks and after every 3 weeks